# Preserves access to affordable drugs

**Bill ID:** A7465
**Session:** 2023
**Sponsor:** Anna Kelles
**Status:** In Assembly Committee

## Summary

Relates to preserving access to affordable drugs; provides that an agreement resolving or settling, on a final or interim basis, a patent infringement claim, in connection with the sale of a pharmaceutical product, shall be presumed to have anticompetitive effects if a nonreference drug filer receives anything of value from another company asserting patent infringement and if the nonreference drug filer agrees to limit or forego research, development, manufacturing, marketing, or sales of the nonreference drug filer's product for any period of time.

---

## Full Text

S T A T E  O F  N E W  Y O R K
 ________________________________________________________________________
 
  7465
 
  2023-2024 Regular Sessions
 
  I N  A S S E M B L Y
 
  May 24, 2023
  ___________
 
 Introduced by M. of A. KELLES, RIVERA, DAVILA, BURDICK, SIMON, SILLITTI,
  EPSTEIN,  L. ROSENTHAL,  WALLACE,  LUPARDO,  GONZALEZ-ROJAS,  PAULIN,
  THIELE,  BICHOTTE HERMELYN,  STECK,  STIRPE,  SMITH,  REYES,  FORREST,
  LAVINE,  JEAN-PIERRE,  JACKSON,  GUNTHER,  HEVESI,  DINOWITZ, MAMDANI,
  GLICK -- read once and referred to the Committee on Health

 AN ACT to amend the public health law, in relation to preserving  access
  to affordable drugs
 
  THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
  Section 1. Article 2-A of the public health law is amended by adding a
 new title IV to read as follows:
  TITLE IV
  PRESERVING ACCESS TO AFFORDABLE DRUGS
 SECTION 282. DEFINITIONS.
  283. PRESERVING ACCESS TO AFFORDABLE DRUGS.
  ยง 282. DEFINITIONS. FOR THE PURPOSES  OF  THIS  TITLE,  THE  FOLLOWING
 TERMS SHALL HAVE THE FOLLOWING MEANINGS:
  1.  "ANDA" SHALL MEAN ABBREVIATED NEW DRUG APPLICATION AS DESCRIBED BY
 505(J) OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT, 21 U.S.C. 335(J).
  2. "ANDA FILER" SHALL MEAN A PARTY THAT OWNS OR CONTROLS AN ANDA FILED
 WITH THE FEDERAL FOOD AND  DRUG  ADMINISTRATION  OR  HAS  THE  EXCLUSIVE
 RIGHTS UNDER THAT ANDA TO DISTRIBUTE THE ANDA PRODUCT.
  3.  "AGREEMENT" SHALL MEAN ANYTHING THAT WOULD CONSTITUTE AN AGREEMENT
 UNDER STATE LAW.
  4. "AGREEMENT RESOLVING  OR  SETTLING  A  PATENT  INFRINGEMENT  CLAIM"
 INCLUDES  ANY  AGREEMENT  THAT IS ENTERED INTO WITHIN THIRTY DAYS OF THE
 RESOLUTION OR THE SETTLEMENT OF THE CLAIM, OR ANY OTHER  AGREEMENT  THAT
 IS CONTINGENT UPON, PROVIDES A CONTINGENT CONDITION FOR, OR IS OTHERWISE
 RELATED  TO  THE  RESOLUTION  OR  SETTLEMENT  OF  THE  CLAIM. THIS SHALL
 INCLUDE, BUT IS NOT LIMITED TO, THE FOLLOWING:

  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
  [ ] is old law to be omitted.
  LBD09108-01-3
 A. 7465  2
 
  (A) ANY AGREEMENT REQUIRED TO BE PROVIDED TO THE FEDERAL TRADE COMMIS-
 SION OR THE ANTITRUST  DIVISION  OF  THE  UNITED  STATES  DEPARTMENT  OF
 JUSTICE  UNDER  THE MEDICARE PRESCRIPTION DRUG, IMPROVEMENT, AND MODERN-
 IZATION ACT OF 2003, PUB. L. NO. 108-173;
  (B)  ANY  AGREEMENT  BETWEEN  A  BIOSIMILAR OR INTERCHANGEABLE PRODUCT
 APPLICANT AND A REFERENCE PRODUCT  SPONSOR  UNDER  THE  BIOLOGICS  PRICE
 COMPETITION  AND  INNOVATION  ACT  OF  2009,  PUB.  L. NO. 111-148, THAT
 RESOLVES PATENT CLAIMS BETWEEN THE APPLICANT AND SPONSOR.
  5. "BIOSIMILAR BIOLOGICAL PRODUCT  APPLICATION  FILER"  SHALL  MEAN  A
 PARTY  THAT OWNS OR CONTROLS A BIOSIMILAR BIOLOGICAL PRODUCT APPLICATION
 FILED WITH THE FEDERAL FOOD AND DRUG ADMINISTRATION PURSUANT TO  SECTION
 351(K) OF THE PUBLIC HEALTH SERVICE ACT, 42 U.S.C. 262(K), FOR LICENSURE
 OF  A  BIOLOGICAL  PRODUCT  AS BIOSIMILAR TO, OR INTERCHANGEABLE WITH, A
 REFERENCE PRODUCT, OR THAT HAS THE EXCLUSIVE RIGHTS UNDER  THE  APPLICA-
 TION TO DISTRIBUTE THE BIOSIMILAR BIOLOGICAL PRODUCT.
  6. "NDA" SHALL MEAN A NEW DRUG APPLICATION.
  7. "NONREFERENCE DRUG FILER" SHALL MEAN EITHER:
  (A) AN ANDA FILER;
  (B)  A COMPANY THAT SEEKS AN ABBREVIATED APPROVAL PATHWAY FOR ITS DRUG
 PRODUCT UNDER 505(B)(2) OF THE FEDERAL FOOD, DRUG, AND  COSMETIC ACT, 21
 U.S.C. 355(B)(2); OR
  (C) A BIOSIMILAR BIOLOGICAL  PRODUCT  APPLICATION  FILER,  OR  COMPANY
 SEEKING FDA APPROVAL FOR A BIOSIMILAR UNDER 42 U.S.C. 262.
  8.  "NONREFERENCE  DRUG PRODUCT" SHALL MEAN THE PRODUCT TO BE MANUFAC-
 TURED UNDER AN ANDA OR AN APPLICATION FILED UNDER SECTION  505(B)(2)  OF
 THE  FEDERAL FOOD, DRUG, AND COSMETIC ACT, 21 U.S.C. 355(B), THAT IS THE
 SUBJECT OF THE PATENT INFRINGEMENT CLAIM, A BIOSIMILAR BIOLOGICAL  PROD-
 UCT  THAT IS THE PRODUCT TO BE MANUFACTURED UNDER THE BIOSIMILAR BIOLOG-
 ICAL PRODUCT APPLICATION THAT IS THE SUBJECT OF THE PATENT  INFRINGEMENT
 CLAIM, OR BOTH.
  9.  "PATENT  INFRINGEMENT" SHALL MEAN INFRINGEMENT OF ANY PATENT OR OF
 ANY FILED PATENT APPLICATION,  EXTENSION,  REISSUE,  RENEWAL,  DIVISION,
 CONTINUATION,  CONTINUATION IN PART, REEXAMINATION, PATENT TERM RESTORA-
 TION, PATENTS OF ADDITION, AND EXTENSIONS THEREOF.
  10. "PATENT INFRINGEMENT CLAIM" SHALL MEAN ANY ALLEGATION  MADE  TO  A
 NONREFERENCE  DRUG  FILER,  WHETHER OR NOT INCLUDED IN A COMPLAINT FILED
 WITH A COURT OF LAW, THAT ITS NONREFERENCE DRUG PRODUCT  OR  APPLICATION
 INFRINGES  ANY PATENT HELD BY, OR EXCLUSIVELY LICENSED TO, THE REFERENCE
 DRUG HOLDER.
  11. "REFERENCE DRUG HOLDER" SHALL MEAN EITHER:
  (A) A BRAND HOLDER THAT IS ANY OF THE FOLLOWING:
  (I) THE HOLDER OF AN APPROVED NDA FOR A DRUG PRODUCT APPLICATION FILED
 UNDER SECTION 505(B) OF THE FEDERAL FOOD, DRUG,  AND  COSMETIC  ACT,  21
 U.S.C. 355(B);
  (II)  A  PERSON OWNING OR CONTROLLING ENFORCEMENT OF THE PATENT LISTED
 IN THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC  EQUIVALENCE  EVALUATIONS
 IN CONNECTION WITH THE NDA; OR
  (III)  THE  PREDECESSORS,  SUBSIDIARIES, DIVISIONS, GROUPS, AND AFFIL-
 IATES CONTROLLED BY, CONTROLLING, OR UNDER COMMON CONTROL WITH,  ANY  OF
 THE  ENTITIES  DESCRIBED  IN SUBPARAGRAPH (I) OR (II) OF THIS PARAGRAPH,
 WITH CONTROL TO BE PRESUMED BY DIRECT OR  INDIRECT  SHARE  OWNERSHIP  OF
 FIFTY  PERCENT  OR GREATER, AS WELL AS THE LICENSEES, LICENSORS, SUCCES-
 SORS, AND ASSIGNS OF EACH OF THOSE ENTITIES; OR
  (B) A BIOLOGICAL PRODUCT LICENSE HOLDER, WHICH SHALL MEAN ANY  OF  THE
 FOLLOWING:
 A. 7465  3
 
  (I)  THE  HOLDER OF AN APPROVED BIOLOGICAL PRODUCT LICENSE APPLICATION
 FOR A BIOLOGICAL DRUG PRODUCT UNDER SECTION 351(A) OF THE PUBLIC  HEALTH
 SERVICE ACT, 42 U.S.C. 262(A);
  (II)  A  PERSON  OWNING OR CONTROLLING ENFORCEMENT OF ANY PATENTS THAT
 CLAIM THE BIOLOGICAL PRODUCT THAT IS THE SUBJECT OF THE APPROVED BIOLOG-
 ICAL PATENT LICENSE APPLICATION; OR
  (III) THE PREDECESSORS, SUBSIDIARIES, DIVISIONS,  GROUPS,  AND  AFFIL-
 IATES  CONTROLLED  BY, CONTROLLING, OR UNDER COMMON CONTROL WITH, ANY OF
 THE ENTITIES DESCRIBED IN SUBPARAGRAPH (I) OR (II)  OF  THIS  PARAGRAPH,
 WITH  CONTROL  TO  BE  PRESUMED BY DIRECT OR INDIRECT SHARE OWNERSHIP OF
 FIFTY PERCENT OR GREATER, AS WELL AS THE LICENSEES,  LICENSORS,  SUCCES-
 SORS, AND ASSIGNS OF EACH OF THOSE ENTITIES.
  12. "REFERENCE DRUG PRODUCT" SHALL MEAN THE PRODUCT TO BE MANUFACTURED
 BY  THE REFERENCE DRUG HOLDER AND INCLUDES BOTH BRANDED DRUGS OF THE NDA
 HOLDER AND THE BIOLOGIC DRUG PRODUCT OF  THE  BIOLOGIC  PRODUCT  LICENSE
 APPLICANT.
  13.  "STATUTORY  EXCLUSIVITY"  SHALL  MEAN  THOSE  PROHIBITIONS ON THE
 APPROVAL OF DRUG APPLICATIONS UNDER CLAUSES (II) THROUGH (IV) OF SECTION
 505(C)(3)(E), SECTION 527 OR SECTION 505A OF THE FEDERAL FOOD, DRUG, AND
 COSMETIC ACT, 21 U.S.C. 355(C)(3)(E), ON  THE  LICENSING  OF  BIOLOGICAL
 PRODUCT  APPLICATIONS  UNDER SECTION 262(K)(7) OF TITLE 42 OF THE UNITED
 STATES CODE OR SECTION 262(M)(2) OR (3) OF TITLE 42 OF THE UNITED STATES
 CODE.
  ยง 283. PRESERVING  ACCESS  TO  AFFORDABLE  DRUGS.  1.  (A)  EXCEPT  AS
 PROVIDED IN PARAGRAPH (C) OF THIS SUBDIVISION, AN AGREEMENT RESOLVING OR
 SETTLING,  ON  A FINAL OR INTERIM BASIS, A PATENT INFRINGEMENT CLAIM, IN
 CONNECTION WITH THE SALE OF A PHARMACEUTICAL PRODUCT, SHALL BE  PRESUMED
 TO HAVE ANTICOMPETITIVE EFFECTS AND SHALL BE A VIOLATION OF THIS SECTION
 IF BOTH OF THE FOLLOWING APPLY:
  (I)  A NONREFERENCE DRUG FILER RECEIVES ANYTHING OF VALUE FROM ANOTHER
 COMPANY ASSERTING PATENT INFRINGEMENT, INCLUDING, BUT NOT LIMITED TO, AN
 EXCLUSIVE LICENSE OR A PROMISE THAT THE BRAND COMPANY WILL NOT LAUNCH AN
 AUTHORIZED GENERIC VERSION OF ITS BRAND DRUG; AND
  (II) THE NONREFERENCE DRUG FILER AGREES TO LIMIT OR  FOREGO  RESEARCH,
 DEVELOPMENT, MANUFACTURING, MARKETING, OR SALES OF THE NONREFERENCE DRUG
 FILER'S PRODUCT FOR ANY PERIOD OF TIME.
  (B)  AS USED IN SUBPARAGRAPH (I) OF PARAGRAPH (A) OF THIS SUBDIVISION,
 "ANYTHING OF VALUE" SHALL BE INTERPRETED BROADLY TO INCLUDE ANY TYPE  OF
 CONSIDERATION,  VALUE OR BENEFIT A REFERENCE DRUG HOLDER OR NONREFERENCE
 DRUG FILER COULD POSSIBLY OBTAIN FROM THE AGREEMENT. "ANYTHING OF VALUE"
 SHALL NOT INCLUDE A SETTLEMENT OF PATENT INFRINGEMENT  CLAIMS  IN  WHICH
 THE  CONSIDERATION GRANTED BY THE REFERENCE DRUG HOLDER TO THE NONREFER-
 ENCE DRUG FILER AS PART OF THE RESOLUTION OR SETTLEMENT CONSISTS OF ONLY
 ONE OR MORE OF THE FOLLOWING:
  (I) THE RIGHT TO MARKET THE COMPETING PRODUCT  IN  THE  UNITED  STATES
 BEFORE THE EXPIRATION OF EITHER:
  (A) A PATENT THAT IS THE BASIS FOR THE PATENT INFRINGEMENT CLAIM; OR
  (B)  A  PATENT RIGHT OR OTHER STATUTORY EXCLUSIVITY THAT WOULD PREVENT
 THE MARKETING OF THE DRUG;
  (II) A COVENANT NOT TO SUE ON A CLAIM THAT THE NONREFERENCE DRUG PROD-
 UCT INFRINGES A UNITED STATES PATENT;
  (III) COMPENSATION FOR SAVED REASONABLE FUTURE LITIGATION EXPENSES  OF
 THE REFERENCE DRUG HOLDER BUT ONLY IF BOTH OF THE FOLLOWING ARE TRUE:
  (A)  THE TOTAL COMPENSATION FOR SAVED LITIGATION EXPENSES IS REFLECTED
 IN BUDGETS THAT THE REFERENCE DRUG  HOLDER  DOCUMENTED  AND  ADOPTED  AT
 LEAST SIX MONTHS BEFORE THE SETTLEMENT; AND
 A. 7465  4
 
  (B) THE COMPENSATION SHALL NOT EXCEED THE LOWER OF THE FOLLOWING:
  (1) SEVEN MILLION FIVE HUNDRED THOUSAND DOLLARS; OR
  (2)  FIVE  PERCENT  OF  THE  REVENUE  THAT THE NONREFERENCE DRUG FILER
 PROJECTED OR FORECASTED IT WOULD RECEIVE IN THE  FIRST  THREE  YEARS  OF
 SALES  OF  ITS  VERSION OF THE REFERENCE DRUG DOCUMENTED AT LEAST TWELVE
 MONTHS BEFORE THE SETTLEMENT. IF NO PROJECTIONS OR FORECASTS ARE  AVAIL-
 ABLE,  THE  COMPENSATION  SHALL  NOT  EXCEED  TWO HUNDRED FIFTY THOUSAND
 DOLLARS;
  (IV) AN AGREEMENT BY THE REFERENCE DRUG HOLDER NOT TO  INTERFERE  WITH
 THE  NONREFERENCE DRUG FILER'S ABILITY TO SECURE AND MAINTAIN REGULATORY
 APPROVAL TO MARKET THE NONREFERENCE DRUG  PRODUCT  OR  AN  AGREEMENT  TO
 FACILITATE  THE NONREFERENCE DRUG FILER'S ABILITY TO SECURE AND MAINTAIN
 REGULATORY APPROVAL TO MARKET THE NONREFERENCE DRUG PRODUCT; OR
  (V) AN AGREEMENT RESOLVING A PATENT INFRINGEMENT CLAIM  IN  WHICH  THE
 REFERENCE  DRUG  HOLDER  FORGIVES  THE  POTENTIAL  DAMAGES  ACCRUED BY A
 NONREFERENCE DRUG FILER FOR AN AT-RISK LAUNCH OF THE  NONREFERENCE  DRUG
 PRODUCT THAT IS THE SUBJECT OF THAT CLAIM.
  (C)  PARTIES  TO AN AGREEMENT ARE NOT IN VIOLATION OF PARAGRAPH (A) OF
 THIS SUBDIVISION  IF  THEY  CAN  DEMONSTRATE  BY  CLEAR  AND  CONVINCING
 EVIDENCE THAT EITHER OF THE FOLLOWING ARE MET:
  (I)  THE  VALUE  RECEIVED  BY THE NONREFERENCE DRUG FILER DESCRIBED IN
 SUBPARAGRAPH (I) OF PARAGRAPH (A) OF THIS  SUBDIVISION  IS  A  FAIR  AND
 REASONABLE  COMPENSATION  SOLELY  FOR  OTHER  GOODS OR SERVICES THAT THE
 NONREFERENCE DRUG FILER HAS PROMISED TO PROVIDE; OR
  (II) THE AGREEMENT HAS DIRECTLY GENERATED PROCOMPETITIVE BENEFITS  AND
 THE  PROCOMPETITIVE  BENEFITS  OF THE AGREEMENT OUTWEIGH THE ANTICOMPET-
 ITIVE EFFECTS OF THE AGREEMENT.
  2. IN DETERMINING WHETHER THE PARTIES TO THE AGREEMENT HAVE MET  THEIR
 BURDEN  UNDER  PARAGRAPH (C) OF SUBDIVISION ONE OF THIS SECTION, A COURT
 OF COMPETENT JURISDICTION SHALL NOT CONSIDER ANY OF THE FOLLOWING:
  (A) THAT ENTRY INTO THE MARKETPLACE COULD NOT HAVE OCCURRED UNTIL  THE
 EXPIRATION  OF  THE  RELEVANT PATENT EXCLUSIVITY OR THAT THE AGREEMENT'S
 PROVISION FOR ENTRY OF THE NONREFERENCE DRUG PRODUCT BEFORE THE  EXPIRA-
 TION  OF  ANY  PATENT EXCLUSIVITY MEANS THAT THE AGREEMENT IS PROCOMPET-
 ITIVE WITHIN THE MEANING OF SUBPARAGRAPH (II) OF PARAGRAPH (C) OF SUBDI-
 VISION ONE OF THIS SECTION;
  (B) THAT ANY PATENT IS ENFORCEABLE AND INFRINGED BY  THE  NONREFERENCE
 DRUG  FILER  IN THE ABSENCE OF A FINAL ADJUDICATION BINDING ON THE FILER
 OF THOSE ISSUES;
  (C) THAT THE AGREEMENT CAUSED NO DELAY IN ENTRY  OF  THE  NONREFERENCE
 DRUG  FILER'S  DRUG PRODUCT BECAUSE OF THE LACK OF FEDERAL FOOD AND DRUG
 ADMINISTRATION (FDA) APPROVAL OF THAT OR OF  ANOTHER  NONREFERENCE  DRUG
 PRODUCT; OR
  (D)  THAT THE AGREEMENT CAUSED NO HARM OR DELAY DUE TO THE POSSIBILITY
 THAT THE NONREFERENCE DRUG FILER'S  DRUG  PRODUCT  MIGHT  INFRINGE  SOME
 PATENT THAT HAS NOT BEEN ASSERTED AGAINST THE NONREFERENCE DRUG FILER OR
 THAT IS NOT SUBJECT TO A FINAL AND BINDING ADJUDICATION ON THAT FILER AS
 TO THE PATENT'S SCOPE, ENFORCEABILITY, AND INFRINGEMENT.
  3.  IN DETERMINING WHETHER THE PARTIES TO THE AGREEMENT HAVE MET THEIR
 BURDEN UNDER PARAGRAPH (C) OF SUBDIVISION ONE OF THIS SECTION,  A  COURT
 OF COMPETENT JURISDICTION SHALL PRESUME THAT THE RELEVANT PRODUCT MARKET
 IS  THAT MARKET CONSISTING OF THE REFERENCE DRUG OF THE COMPANY ALLEGING
 PATENT INFRINGEMENT AND THE DRUG PRODUCT OF THE NONREFERENCE DRUG  FILER
 ACCUSED  OF  INFRINGEMENT  AND  ANY  OTHER  BIOLOGICAL  PRODUCT  THAT IS
 LICENSED AS BIOSIMILAR OR IS AN AB-RATED GENERIC TO THE REFERENCE  PROD-
 UCT.
 A. 7465  5
 
  4.  (A) THIS SECTION SHALL NOT MODIFY, IMPAIR, LIMIT, OR SUPERSEDE THE
 APPLICABILITY OF THE ANTITRUST LAWS OF THE  STATE  PURSUANT  TO  ARTICLE
 TWENTY-TWO  OF  THE GENERAL BUSINESS LAW, UNFAIR COMPETITION LAWS OF THE
 STATE PURSUANT TO ARTICLE TWENTY-TWO-A OF THE GENERAL  BUSINESS  LAW  OR
 THE  AVAILABILITY  OF DAMAGES OR REMEDIES PROVIDED THEREIN. THIS SECTION
 SHALL NOT MODIFY, IMPAIR, LIMIT, OR SUPERSEDE  THE  RIGHT  OF  ANY  DRUG
 COMPANY  APPLICANT TO ASSERT CLAIMS OR COUNTERCLAIMS AGAINST ANY PERSON,
 UNDER THE ANTITRUST LAWS OR OTHER LAWS RELATING TO UNFAIR COMPETITION OF
 THE FEDERAL ANTITRUST LAW OR STATE LAW.
  (B) IF ANY PROVISION OF THIS SUBDIVISION, AN AMENDMENT  MADE  TO  THIS
 SUBDIVISION,  OR  THE  APPLICATION  OF ANY PROVISION OR AMENDMENT TO ANY
 PERSON OR CIRCUMSTANCE IS HELD TO BE UNCONSTITUTIONAL, THE REMAINDER  OF
 THIS  SUBDIVISION,  THE  AMENDMENTS  MADE  TO  THIS SUBDIVISION, AND THE
 APPLICATION OF THE PROVISIONS OF THIS SUBDIVISION OR AMENDMENTS  TO  ANY
 PERSON OR CIRCUMSTANCE SHALL NOT BE AFFECTED.
  5.  (A)(I)  EACH  PERSON  THAT VIOLATES OR ASSISTS IN THE VIOLATION OF
 THIS SECTION SHALL FORFEIT AND PAY TO THE STATE A CIVIL  PENALTY  SUFFI-
 CIENT TO DETER VIOLATIONS OF THIS SECTION, AS FOLLOWS:
  (A)  IF THE PERSON WHO VIOLATED THIS SECTION RECEIVED ANY VALUE DUE TO
 THAT VIOLATION, AN AMOUNT UP TO THREE TIMES THE VALUE  RECEIVED  BY  THE
 PARTY  THAT IS REASONABLY ATTRIBUTABLE TO THE VIOLATION OF THIS SECTION,
 OR TWENTY MILLION DOLLARS, WHICHEVER IS GREATER; OR
  (B) IF THE VIOLATOR HAS NOT RECEIVED ANYTHING OF VALUE AS DESCRIBED IN
 THIS SUBPARAGRAPH, AN AMOUNT UP TO THREE TIMES THE VALUE GIVEN TO  OTHER
 PARTIES  TO  THE  AGREEMENT  REASONABLY ATTRIBUTABLE TO THE VIOLATION OF
 THIS SECTION, OR TWENTY MILLION DOLLARS.
  (C) FOR PURPOSES OF THIS SUBDIVISION, "REASONABLY ATTRIBUTABLE TO  THE
 VIOLATION"  SHALL  BE  DETERMINED BY THE STATE'S SHARE OF THE MARKET FOR
 THE BRAND DRUG AT ISSUE IN THE AGREEMENT.
  (II) ANY PENALTY DESCRIBED IN SUBPARAGRAPH (I) OF THIS PARAGRAPH SHALL
 ACCRUE ONLY TO THE STATE AND  SHALL  BE  RECOVERED  IN  A  CIVIL  ACTION
 BROUGHT BY THE ATTORNEY GENERAL IN ITS OWN NAME, OR BY ANY OF ITS ATTOR-
 NEYS  DESIGNATED  BY IT FOR THAT PURPOSE, AGAINST ANY PARTY TO AN AGREE-
 MENT THAT VIOLATES THIS SECTION.
  (B) EACH PARTY THAT VIOLATES OR  ASSISTS  IN  THE  VIOLATION  OF  THIS
 SECTION SHALL BE LIABLE FOR ANY DAMAGES, PENALTIES, COSTS, FEES, INJUNC-
 TIONS,  OR OTHER EQUITABLE OR LEGAL REMEDIES, INCLUDING, BUT NOT LIMITED
 TO, RESTITUTION AND DISGORGEMENT, THAT MAY BE JUST AND REASONABLE.  SUCH
 REMEDIES SHALL INCLUDE, BUT NOT BE  LIMITED  TO,  ANY  REMEDY  AVAILABLE
 UNDER  ARTICLES  TWENTY-TWO  OR TWENTY-TWO-A OF THE GENERAL BUSINESS LAW
 AND SECTION SIXTY-THREE OF THE EXECUTIVE LAW.
  (C) IF THE STATE IS AWARDED PENALTIES UNDER SUBPARAGRAPH (I) OF  PARA-
 GRAPH  (A)  OF THIS SUBDIVISION, IT SHALL NOT RECOVER PENALTIES PURSUANT
 TO ANOTHER LAW IDENTIFIED IN PARAGRAPH (B)  OF  THIS  SUBDIVISION.  THIS
 SECTION SHALL NOT BE CONSTRUED TO FORECLOSE THE STATE'S ABILITY TO CLAIM
 ANY  EQUITABLE OR LEGAL REMEDY AVAILABLE IN PARAGRAPH (B) OF THIS SUBDI-
 VISION.
  (D) AN ACTION TO ENFORCE A CAUSE OF ACTION FOR  A  VIOLATION  OF  THIS
 SECTION  SHALL  BE  COMMENCED WITHIN SIX YEARS AFTER THE CAUSE OF ACTION
 ACCRUED.
  ยง 2. Severability clause. If any clause, sentence, paragraph, subdivi-
 sion, section or part of this act shall be  adjudged  by  any  court  of
 competent  jurisdiction  to  be  invalid or unenforceable, such judgment
 shall not affect, impair, or invalidate the remainder thereof, but shall
 be confined in its operation to the clause, sentence, paragraph,  subdi-
 vision,  section or part thereof directly involved in the controversy in
 A. 7465  6
 
 which such judgment shall have been rendered. It is hereby  declared  to
 be  the  intent of the legislature that this act would have been enacted
 even if such invalid provisions had not been included herein.
  ยง  3.  This  act  shall take effect on the sixtieth day after it shall
 have become a law.